News - Panacos Pharmaceuticals Inc.
Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced its financial results for the third quarter of 2008 and reviewed progress in its development programs.
Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will report its financial results for the third quarter of 2008 after the U.S. Financial Markets close on Wednesday, November 5, 2008.
Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) announced today the bevirimat Study 204 achieved its primary objective by demonstrating bevirimat plasma levels in HIV-positive patients to be in a target range for virologic reduction.